Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Phase III, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Assess Efficacy and Safety of Early Administration of Ivermectin During 3 Consecutive Days to Prevent SARS CoV-2 (COVID-19) Hospitalisation in Adults Older Than 50 Years of Age

NCT05993143 is registered in ClinicalTrials.gov with Insud Pharma as lead sponsor.

NCT NCT05993143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Phase III, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Assess Efficacy and Safety of Early Administration of Ivermectin During 3 Consecutive Days to Prevent SARS CoV-2 (COVID-19) Hospitalisation in Adults Older Than 50 Years of Age
Lead sponsor
Insud Pharma
Phase
Phase 3
Overall status
Terminated
Start date
January 18, 2021
Completion date
July 21, 2021
Enrollment
249 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2